Last reviewed · How we verify
NCT04290871: NOSARSCOVID
Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.
Phase 2 trial testing Nitric Oxide Gas in Coronavirus Covid-19 Infection Variant Omicron. Withdrawn.
31 December 2023
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Start date | 16 January 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 April 2024 |
Drugs / interventions tested
- Nitric Oxide Gas — full drug profile →
- The delivery system will be set up anyway without study gas administration
Conditions studied
- Coronavirus Covid-19 Infection Variant Omicron — all drugs for Coronavirus Covid-19 Infection Variant Omicron →
- SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →
Sponsor
Xijing Hospital
Who can join
18 and older, any sex, with Coronavirus Covid-19 Infection Variant Omicron or SARS (Severe Acute Respiratory Syndrome). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will enroll 104 patients with severe COVID-19 infection that mechanical ventilation is needed for respiratory support. Patients will be randomized to receive either inhaled nitric oxide (per protocol) or a placebo. ICU Standards of care will be the institution's own protocols (such as ventilation strategies and use and dose of antivirals and antimicrobials, steroids, inotropic and vasopressor agents).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044 -
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006 -
Emerging treatment strategies for COVID-19 infection.
Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, et al · · 2021 · cited 209× · PMID 33128197 · DOI 10.1007/s10238-020-00671-y -
Emerging Mechanisms of Pulmonary Vasoconstriction in SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) and Potential Therapeutic Targets.
Karmouty-Quintana H, Thandavarayan RA, Keller SP, Sahay S, et al · · 2020 · cited 42× · PMID 33138181 · DOI 10.3390/ijms21218081 -
Outbreak of COVID-19: An emerging global pandemic threat.
Peng M. · · 2020 · cited 42× · PMID 32768974 · DOI 10.1016/j.biopha.2020.110499 -
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, et al · · 2020 · cited 29× · PMID 32623296 · DOI 10.1016/j.ctrv.2020.102063 -
Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.
Oroojalian F, Haghbin A, Baradaran B, Hemmat N, et al · · 2020 · cited 27× · PMID 32991900 · DOI 10.1016/j.ijbiomac.2020.09.204 -
Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections.
Bath PM, Coleman CM, Gordon AL, Lim WS, et al · · 2021 · cited 25× · PMID 35685687 · DOI 10.12688/f1000research.51270.2
Verify or expand the search:
- PubMed search for NCT04290871
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nitric Oxide Gas
Trials testing the same drug.
- NCT06702553 — Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass · Phase 3 · recruiting
- NCT05721144 — Inhaled NO in Surgical Patients With Recent COVID-19 Infection · Phase 2 · completed
- NCT04338828 — Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED · Phase 2 · terminated
- NCT04306393 — Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 · Phase 2 · completed
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04290871 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 8 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04290871.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing